Segra International will soon begin operations in the United States, providing plant tissue culture services to growers in the emerging federally legal U.S. hemp market.
Following the passage of the Agricultural Improvement Act of 2018, hemp was removed from the U.S. Drug Enforcement Agency’s Schedule I drug listing, and is now considered an “agricultural commodity.” Many new U.S. hemp operations are focused on the production of cannabidiol (CBD), a high-value compound found in cannabis plants. However, compliance with U.S. federal law requires that tetrahydrocannabinol (THC) levels in hemp crops remain below 0.3 percent. "Segra, along with its genetics partners, intends to offer U.S. hemp growers access to premium and exclusive high-CBD, low-THC cultivars," the team with the company explains.
“Our primary focus in this emerging market is the production of high-CBD plantlets utilizing our proprietary plant tissue culture technology. The standardised nature of Segra’s tissue culture nursery stock will provide substantial increased value and risk mitigation for hemp growers; we look forward to supporting the propagation needs of hemp farmers across the U.S. in the near future,” said Ian Davidson, Segra’s chief business development officer.
The company has leased a 1,900-square-foot laboratory facility in Portland, Ore., and has applied for the state’s industrial hemp license. It is anticipated that Segra’s U.S. hemp operations will commence later this year.
For more information:
Segra International Corp.
#108 – 21300 Gordon Way
Canada V6W 1M2